We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Globus Medical (GMED) Q1 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Globus Medical (GMED - Free Report) is expected to reveal quarterly earnings of $0.74 per share, indicating an increase of 2.8% compared to the year-ago period. Analysts forecast revenues of $628.32 million, representing an increase of 3.6% year over year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Globus Medical metrics that are routinely monitored and predicted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net Sales by Product Category- Enabling Technologies' of $38.79 million. The estimate indicates a change of +21.3% from the prior-year quarter.
Analysts forecast 'Net Sales by Product Category- Musculoskeletal Solutions' to reach $598.85 million. The estimate points to a change of +4.2% from the year-ago quarter.
The consensus among analysts is that 'Geographic Revenues- International' will reach $127.52 million. The estimate indicates a year-over-year change of +3.1%.
Based on the collective assessment of analysts, 'Geographic Revenues- United States' should arrive at $510.72 million. The estimate points to a change of +5.8% from the year-ago quarter.
Over the past month, Globus Medical shares have recorded returns of +4.5% versus the Zacks S&P 500 composite's +0.4% change. Based on its Zacks Rank #3 (Hold), GMED will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gear Up for Globus Medical (GMED) Q1 Earnings: Wall Street Estimates for Key Metrics
The upcoming report from Globus Medical (GMED - Free Report) is expected to reveal quarterly earnings of $0.74 per share, indicating an increase of 2.8% compared to the year-ago period. Analysts forecast revenues of $628.32 million, representing an increase of 3.6% year over year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
Given this perspective, it's time to examine the average forecasts of specific Globus Medical metrics that are routinely monitored and predicted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net Sales by Product Category- Enabling Technologies' of $38.79 million. The estimate indicates a change of +21.3% from the prior-year quarter.
Analysts forecast 'Net Sales by Product Category- Musculoskeletal Solutions' to reach $598.85 million. The estimate points to a change of +4.2% from the year-ago quarter.
The consensus among analysts is that 'Geographic Revenues- International' will reach $127.52 million. The estimate indicates a year-over-year change of +3.1%.
Based on the collective assessment of analysts, 'Geographic Revenues- United States' should arrive at $510.72 million. The estimate points to a change of +5.8% from the year-ago quarter.
View all Key Company Metrics for Globus Medical here>>>
Over the past month, Globus Medical shares have recorded returns of +4.5% versus the Zacks S&P 500 composite's +0.4% change. Based on its Zacks Rank #3 (Hold), GMED will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>